First CRISPR/Cas9 Gene-Edited Therapy Authorized by the UK MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
16 November 2023
The First regulatory authorization of a CRISPR-based gene-editing therapy in the world has been granted to Vertex Therapeutics Inc. and CRISPR Therapeutics by the UK MHRA for condition marketing authorization for CASGEVY™.
6 December 2023
Oxford Biomedica Acquires ABL Europe
5 December 2023
Two female pediatric patients with
29 November 2023
FDA investigates T cell malignancy
28 November 2023
Sernova’s Hemophilia A Program Receives Orphan Drug and Rare Pediatric Disease Designations from FDA
Sernova has announced that the
23 November 2023
Clinical results of a gene
22 November 2023
AskBio has announced that the
